Mandate

Acquisition of Alvedon approved

April 07, 2009

The Swedish Competition Authority has, following an in-depth investigation, on 3 April 2009 cleared GlaxoSmithKline’s acquisition of a portfolio of drugs, including i.a. the brand Alvedon, from AstraZeneca.

Alvedon is the leading painkiller brand in Sweden. GlaxoSmithKline controlled already prior to the acquisition Panodil, one of the main competing brands. The transaction was notified by the parties on 22 December 2008.
The Competition Authority carried out an extensive market investigation and retained external expertise to simulate the effects of the combination.

“Although the transaction involved a strong market position in painkillers based on paracetamol, the Competition Authority could eventually conclude that the transaction did not significantly impede the existence or development of effective competition. The Competition Authority’s decision is, of course, satisfactory for the parties but also of principle importance”, says Johan Karlsson, responsible partner for Vinge’s competition team, who acted for AstraZeneca.

“It is one of the few cases where efficiencies made a real difference for the outcome. The decision also shows that the Competition Authority, which it should do, could also take into account future changes in the market place, in this case the liberalization of the pharmaceutical market.”

Vinge advised AstraZeneca. Vinge’s competition team included Johan Karlsson (responsible partner), Mattias Ganslandt (economist), Per Karlsson (counsel), Peter Alstergren (associate) and Carl Johan Sundqvist (associate).   

Vinge hones its offering within capital requirements and risk management in the financial services sector

In order to further strenghthen its service offering within the Banking & Finance and Regulatory practice area, Vinge has formed a team within the capital requirements and risk management in the financial services sector. Torbjörn Jacobsson, whose background includes, among other things, head of risk in the banking sector, has been recruited to lead the group as a senior specialist in relation to issues concerning financial risks and capital requirements.
November 30, 2021

Emelie Svensäter Jerntorp appointed as new partner

Commencing 1 January 2022, Emelie Svensäter Jerntorp will become a partner at Vinge’s Skåne office.
November 19, 2021

Sweden proposes a new law on investment screening which will have significant implications for transactions

Contrary to the situation in many other countries, there are currently only limited possibilities to regulate or prevent foreign direct investments in Sweden that could entail risks to Swedish security interests. Existing regulatory frameworks, such as the Protective Security Act (Sw. Säkerhetsskyddslagen), are limited to certain areas, to certain activities and to specific situations. The final report of the Inquiry of foreign direct investments (Sw. Granskning av utländska direktinvesteringar), published on 1 November 2021, puts forward a proposal for new legislation to address this gap.
November 04, 2021